Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 4 (April)

1. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
   J Clin Oncol, 25(10): 1169-75. [Abstract] [Full-text]
2. C-reactive protein concentrations and subsequent ovarian cancer risk.
   Obstet Gynecol, 109(4): 933-41. [Abstract] [Full-text]
3. Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells.
   J Cell Sci, 120: 1393-404. [Abstract] [Full-text]
4. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
   Mol Cell Endocrinol, 269(1): 17-25. [Abstract] [Full-text]
5. LH/hCG action and development of ovarian cancer--a short review on biological and clinical/epidemiological aspects.
   Mol Cell Endocrinol, 269(1): 61-4. [Abstract] [Full-text]
6. Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo.
   Int J Cancer, 120(10): 2243-50. [Abstract] [Full-text]
7. A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships.
   Psychooncology, 16(4): 320-8. [Abstract] [Full-text]
8. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
   Am J Obstet Gynecol, 196(4): 389.e1-9; discussion 389.e9-10. [Abstract] [Full-text]
9. Macrophage migration inhibitory factor expression in ovarian cancer.
   Am J Obstet Gynecol, 196(4): 348.e1-5. [Abstract] [Full-text]
10. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Am J Obstet Gynecol, 196(4): e6-9. [Abstract] [Full-text]
11. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
    Clin Cancer Res, 13(7): 2191-8. [Abstract] [Full-text]
12. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
    Br J Cancer, 96(7): 1083-91. [Abstract] [Full-text]
13. Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse.
    Int J Cancer, 120(11): 2339-43. [Abstract] [Full-text]
14. Social support among women who died of ovarian cancer.
    Support Care Cancer, 15(5): 547-56. [Abstract] [Full-text]
15. Ovarian clear cell adenocarcinoma: a continuing enigma.
    J Clin Pathol, 60(4): 355-60. [Abstract] [Full-text]
16. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Cancer Res, 67(7): 3239-53. [Abstract] [Full-text]
17. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
    Cancer Res, 67(7): 3074-84. [Abstract] [Full-text]
18. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.
    Cancer Res, 67(7): 3036-42. [Abstract] [Full-text]
19. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
    Cancer Res, 67(7): 3027-35. [Abstract] [Full-text]
20. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells.
    Cancer Res, 67(7): 2964-71. [Abstract] [Full-text]
21. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Anticancer Drugs, 18(5): 611-7. [Abstract] [Full-text]
22. Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors).
    Am J Surg Pathol, 31(4): 592-7. [Abstract] [Full-text]
23. Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion?
    Am J Surg Pathol, 31(4): 546-54. [Abstract] [Full-text]
24. Low-grade fibromyxoid sarcoma presenting clinically as a primary ovarian neoplasm: a case report.
    Int J Gynecol Pathol, 26(2): 173-6. [Abstract] [Full-text]
25. Primary ovarian adenofibromatous neoplasms with mucin-containing signet-ring cells: a report of 2 cases.
    Int J Gynecol Pathol, 26(2): 165-72. [Abstract] [Full-text]
26. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier.
    Int J Gynecol Pathol, 26(2): 160-4. [Abstract] [Full-text]
27. Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary.
    Int J Gynecol Pathol, 26(2): 154-9. [Abstract] [Full-text]
28. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Int J Gynecol Pathol, 26(2): 147-53. [Abstract] [Full-text]
29. Expression of extracellular matrix proteins in ovarian serous tumors.
    Int J Gynecol Pathol, 26(2): 141-6. [Abstract] [Full-text]
30. Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis?
    Int J Gynecol Pathol, 26(2): 134-40. [Abstract] [Full-text]
31. Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells.
    Exp Cell Res, 313(7): 1307-17. [Abstract] [Full-text]
32. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Cancer Cell, 11(4): 321-33. [Abstract] [Full-text]
33. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    J Clin Oncol, 25(11): 1383-9. [Abstract] [Full-text]
34. Meta-analysis of BRCA1 and BRCA2 penetrance.
    J Clin Oncol, 25(11): 1329-33. [Abstract] [Full-text]
35. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
    Cancer Epidemiol Biomarkers Prev, 16(4): 783-8. [Abstract] [Full-text]
36. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
    Hum Mutat, 28(5): 477-85. [Abstract] [Full-text]
37. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer.
    Mol Cancer Ther, 6(4): 1379-86. [Abstract] [Full-text]
38. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children.
    Fertil Steril, 87(4): 896-901. [Abstract] [Full-text]
39. Some characteristics and purification of anti-(human ovarian carcinoma)xanti-(human CD3) single-chain bispecific antibody.
    Biotechnol Appl Biochem, 47: 39-47. [Abstract] [Full-text]
40. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival.
    Int J Cancer, 120(12): 2710-4. [Abstract] [Full-text]
41. Amplicon profiles in ovarian serous carcinomas.
    Int J Cancer, 120(12): 2613-7. [Abstract] [Full-text]
42. Soluble isoforms but not the transmembrane form of coxsackie-adenovirus receptor are of clinical relevance in epithelial ovarian cancer.
    Int J Cancer, 120(12): 2568-75. [Abstract] [Full-text]
43. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells.
    Cancer Res, 67(8): 3683-90. [Abstract] [Full-text]
44. Appendiceal adenocarcinoma presenting with bilateral Krukenberg tumors.
    J Obstet Gynaecol Res, 33(2): 211-4. [Abstract] [Full-text]
45. A case of pulmonary type of ovarian small cell carcinoma.
    J Obstet Gynaecol Res, 33(2): 203-6. [Abstract] [Full-text]
46. Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer: does ethnicity matter?
    J Obstet Gynaecol Res, 33(2): 155-60. [Abstract] [Full-text]
47. Marantic endocarditis (NBTE) with systemic emboli and paraneoplastic cerebellar degeneration: uncommon presentation of ovarian cancer.
    J Neurooncol, 83(1): 81-3. [Abstract] [Full-text]
48. Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions.
    Oncogene, 26(18): 2574-84. [Abstract] [Full-text]
49. Non-genomic actions of progesterone in the normal and neoplastic mammalian ovary.
    Semin Reprod Med, 25(3): 198-207. [Abstract] [Full-text]
50. The Anti-Mullerian hormone and ovarian cancer.
    Hum Reprod Update, 13(3): 265-73. [Abstract] [Full-text]
51. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Crit Rev Oncol Hematol, 62(2): 137-47. [Abstract] [Full-text]
52. Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by transplatinum planar amine complexes.
    Biochem Pharmacol, 73(11): 1749-57. [Abstract] [Full-text]
53. Retrieval of immature oocytes followed by in vitro maturation and vitrification: a case report on a new strategy of fertility preservation in women with borderline ovarian malignancy.
    Gynecol Oncol, 105(2): 542-4. [Abstract] [Full-text]
54. Risk factors for ovarian cancer histotypes.
    Eur J Cancer, 43(7): 1208-13. [Abstract] [Full-text]
55. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET.
    Gynecol Oncol, 105(2): 545-7. [Abstract] [Full-text]
56. Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
    Gynecol Oncol, 105(2): 548-52. [Abstract] [Full-text]
57. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
    Gynecol Oncol, 105(2): 395-8. [Abstract] [Full-text]
58. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort.
    Gynecol Oncol, 105(2): 365-72. [Abstract] [Full-text]
59. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer.
    Gynecol Oncol, 105(2): 341-50. [Abstract] [Full-text]
60. Ovarian cancer specific kallikrein profile in effusions.
    Gynecol Oncol, 105(2): 501-7. [Abstract] [Full-text]
61. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
    Gynecol Oncol, 105(2): 291-8. [Abstract] [Full-text]
62. Objective risk definition for endometrial lesion spectrum: a diagnostic algorithm.
    Gynecol Oncol, 105(2): 451-6. [Abstract] [Full-text]
63. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
    Gynecol Oncol, 105(2): 481-92. [Abstract] [Full-text]
64. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
    Gynecol Oncol, 105(2): 404-8. [Abstract] [Full-text]
65. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
    Gynecol Oncol, 105(2): 399-403. [Abstract] [Full-text]
66. Ovarian cancer during pregnancy: analysis of 15 cases.
    Gynecol Oncol, 105(2): 446-50. [Abstract] [Full-text]
67. Renal artery thrombosis following secondary cytoreduction in a patient with ovarian cancer.
    Gynecol Oncol, 105(2): 536-8. [Abstract] [Full-text]
68. Vascular endothelial growth factor gene polymorphisms in ovarian cancer.
    Gynecol Oncol, 105(2): 385-9. [Abstract] [Full-text]
69. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
    Gynecol Oncol, 105(2): 373-84. [Abstract] [Full-text]
70. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
    Gynecol Oncol, 105(2): 312-20. [Abstract] [Full-text]
71. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer.
    Gynecol Oncol, 105(2): 409-13. [Abstract] [Full-text]
72. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
    Gynecol Oncol, 105(2): 358-64. [Abstract] [Full-text]
73. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer.
    Gynecol Oncol, 105(2): 414-7. [Abstract] [Full-text]
74. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature.
    Gynecol Oncol, 105(2): 321-4. [Abstract] [Full-text]
75. Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer.
    Cancer Lett, 251(1): 164-7. [Abstract] [Full-text]
76. Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence.
    Cancer Lett, 251(1): 43-52. [Abstract] [Full-text]
77. Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes.
    Cancer Lett, 251(1): 96-104. [Abstract] [Full-text]
78. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Adv Anat Pathol, 14(3): 149-77. [Abstract] [Full-text]
79. Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells.
    FEBS Lett, 581(9): 1825-33. [Abstract] [Full-text]
80. A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2.
    Am J Pathol, 170(5): 1594-606. [Abstract] [Full-text]
81. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
    Am J Surg Pathol, 31(5): 774-82. [Abstract] [Full-text]
82. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Am J Surg Pathol, 31(5): 653-63. [Abstract] [Full-text]
83. Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study.
    BMC Cancer, 7: 60. [Abstract] [Full-text]
84. Mannan-binding lectin (MBL) in women with tumours of the reproductive system.
    Cancer Immunol Immunother, 56(7): 959-71. [Abstract] [Full-text]
85. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
    Oncogene, 26(19): 2736-46. [Abstract] [Full-text]
86. Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.
    Int J Cancer, 121(1): 6-11. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.